Background: Binding sites for agonists and competitive antagonists (nondepolarizing neuromuscular blocking agents) are located at the ␣-␦ and ␣subunit interfaces of adult nicotinic acetylcholine receptors. Most information about the amino acids that participate in antagonist binding comes from binding studies with (؉)-tubocurarine and metocurine. These bind selectively to the ␣interface but are differentially sensitive to mutations. To test the generality of this observation, the authors measured current inhibition by five competitive antagonists on wild-type and mutant acetylcholine receptors.
THE muscle-type nicotinic acetylcholine receptor channel (nAChR) is the prototypical member of the Cys-loop ligand-gated ion channel superfamily. 1 These proteins are composed of ␣ 1 , ␤ 1 , ␦, and ␥ or subunits arranged as transmembrane pentamers: (␣ 1 )(␤ 1 )␦(␣ 1 )␥ in the embryonic nAChR subtype and (␣ 1 )(␤ 1 )␦(␣ 1 ) in the adult nAChR subtype (clockwise, as viewed from the synapse). There are several reasons why so much is known about this protein. Biochemical and structural studies take advantage of the abundance of nAChR in tissue from Torpedo electric organ. 2 Electrophysiologic measurements are aided by its stability in patch clamp experiments. And the discovery 3 and structure determination 4 of a water-soluble analog to the extracellular domain of the receptor, acetylcholine binding protein (AChBP), has led to inferences about structure-function relations of the nAChR. 5 Mutagenesis, functional, labeling, and structural studies have provided detailed information about the ligand binding site in the nAChR ( fig. 1A ). Binding sites for agonists and competitive antagonists are located at the ␣-␦ and ␣-(or ␣-␥) subunit interfaces.** Studies have identified seven noncontinuous "loops" of amino acids that participate in agonist and competitive antagonist binding to the nAChR: loops A-C are on the ␣ subunit (primary component of the binding site), and loops D-G are on the non-␣ subunit (complementary component of the binding site). The three dimensional arrangement of these loops became apparent by making analogies to the structure of AChBP. 4, 6 AChBP is composed of 10 ␤ strands arranged in an immunoglobulin-like topology. Several of the loops are located between the ␤ strands, and the loops from the primary and complementary components come together at the interface between subunits. The binding site is centered around a conserved tryptophan in loop B that provides stability for the quaternary nitrogen moiety of agonists and antagonists via a strongcation interaction. 7 Four additional aromatic amino acids are distributed around the primary and complementary components. The C loop may act as a cap that closes upon binding of agonist and greatly decreases the agonist dissociation rate. 8 The amino acids on the complementary component are not conserved between the ␥, ␦, and subunits; this leads to subunit specificity for ligand binding.
Agonists such as acetylcholine have a higher affinity for the ␣-␦ interface compared with the ␣interface; the extent of the difference depends on both species (Torpedo receptors exhibit a 100-fold preference for acetylcholine binding to the ␣-␦ interface 9 ) and subtype (fetal mouse receptors exhibit a 32-fold preference, 10 and adult mouse receptors exhibit very little preference 11 ). Both sites must be occupied for efficient opening of the channel. 11 Some competitive antagonists are known to bind differently to the two sites. Metocurine, for example, has a 70-to 170-fold higher affinity for the ␣interface compared with the ␣-␦ interface. 12, 13 Occupation of just one of the sites by a competitive antagonist is sufficient to prevent channel opening. Most of the information about the residues that participate in antagonist binding comes from studies of either (ϩ)tubocurarine or metocurine. 14 Even for these similar ligands (metocurine has three additional methyl groups; fig. 1 ), there are differences in sensitivities to mutations. Using computational chemistry to dock ligands to a homology model of the nAChR, Wang et al. 15 showed that (ϩ)-tubocurarine and metocurine bind with different orientations within the ␣interface and have different contacts with the amino acid residues there.
Although the clinical action of competitive nAChR antagonists, muscle paralysis, is a straightforward consequence of their molecular action, there are outstanding questions about the effects of nondepolarizing muscle relaxants. Specific issues include the mechanisms of tetanic fade 16 and of muscle relaxant synergy. 17 Although these phenomena are often ascribed to actions on presynaptic nAChRs, postsynaptic explanations may still be viable. As a first step to address these questions, we use a functional determination of current inhibition to examine competitive antagonism by (ϩ)-tubocurarine, metocurine, pancuronium, vecuronium, and cisatracurium (fig. 1B) on mouse adult wild-type and five mutant nAChRs. We chose these mutations because they have been shown to affect metocurine and/or (ϩ)-tubocurarine binding. 13, 15, 18, 19 The ␣Y198F mutation is in loop C, and the D59 mutations and D173 mutations are in loops E and G, respectively. We used the ␦D180K mutation to test the strength of binding to the ␣-␦ interface. We postulated that the antagonists would show different sensitivities to mutations but that all of them would have a higher affinity for the ␣interface compared with the ␣-␦ interface.
Materials and Methods
HEK293 cells (American Type Culture Collection, Manassas, VA) were transfected using either a calcium phosphate precipitate 20 or a lipid based reagent (FuGENE 6; Roche Diagnostics, Basel, Switzerland). Some experiments were performed using the BOSC23 cell line, a subclone of HEK293 that exhibits higher expression levels. Identical results were obtained using both cell lines. Cells were transfected with complementary DNA (cDNA) coding for subunits of mouse muscle nAChR: ␣, wild type or Y198F; ␤, wild type; , wild type, D59A, D59N, D173A, or D173N; ␦, wild type and cotransfected with cDNA for the ␣ subunit of human CD8 (gift of Brian Seed, Ph.D., Professor of Genetics and Health Sciences and Technology, Harvard Medical School, Cambridge, Massachusetts), a T-cell antigen used as a marker. 21, 22 The AChR cDNA was cloned into the pRBG4 expression vector; the CD8 cDNA was cloned into the H3-CD8 expression plasmid. The wild type and most of the mutant cDNAs 13 were gifts of Steven Sine, Ph.D. (Professor of Physiology, Mayo Clinic, Rochester, Minnesota). DNA sequencing confirmed the constructs. Measurements were performed on cells between 1 and 4 days after transfection. For the experiments with ␣ 2 ␤␦ 2 receptors, we doubled the amount of ␦ subunit cDNA and omitted the subunit cDNA in the transfection mixture.
Acetylcholine chloride (purity Ͼ 99%), (ϩ)-tubocurarine chloride (purity 98%), and pancuronium dibromide (purity Ͼ 99%) were obtained from Sigma-Aldrich Corp. (St. Louis, MO). Metocurine iodide was synthesized from (ϩ)-tubocurarine 23 at the Chemical Synthesis Center, Department of Chemistry, Stony Brook University (Stony Brook, NY). Purity of 99% was determined by 1 H-nuclear magnetic resonance. Vecuronium bromide was obtained as the clinical formulation from Bedford Laboratories (Bedford, OH), 1 mg/ml (1.8 mM) in a solution containing 2.1 mg/ml anhydrous citric acid, 1.6 mg/ml sodium phosphate, and 9.7 mg/ml mannitol. Dilutions were prepared in distilled water. The highest concentration of vecuronium used, 1 M, contained 95 M mannitol. Cisatracurium besylate was obtained as the clinical formulation from GlaxoSmithKline (Philadelphia, PA), 2 mg/ml (2.1 mM) in a 35% benzene sulfonic acid solution. Dilutions were prepared in distilled water. The highest concentration of cisatracurium used, 1 M, contained 0.017% benzene sulfonic acid.
Cells were prepared for patch clamp recording by replacing the culture medium with an extracellular solution consisting of 150 mM NaCl, 5.6 mM KCl, 1.8 mM CaCl 2 , 1.0 mM MgCl 2 , and 10 mM HEPES, pH 7.3. Subsequently, 3-5 l of polystyrene beads coated with a monoclonal antibody specific for the CD8 antigen (Dynabeads; Dynal, Lake Success, NY) were added to the culture dish. Good expression of nAChR channels in excised patches was found for most cells having two or three beads attached.
Patch pipettes, filled with a solution consisting of 140 mM KCl, 5 mM EGTA, 5 mM MgCl 2 , and 10 mM HEPES, pH 7.3, had resistances of 3-6 M⍀. An outsideout patch 24 with a seal resistance of 5 G⍀ or greater was excised from a cell and moved into position at the outflow of a HSSE-2 rapid perfusion device (ALA Scientific Instruments, Westbury, NY). The perfusion sys-tem consisted of solution reservoirs, manual switching valves, a solenoid-driven pinch valve, and two tubes inserted into the culture dish and had a time resolution of less than 100 s. 25 One tube contained extracellular solution without agonist (normal solution); the other contained extracellular solution with 300 M acetylcholine (test solution). In the control protocol, the patch, initially perfused with normal solution, was exposed to a series of ten 0.25-s exposures to the test solution at 5-s intervals. Manual valves were used to connect to reservoirs containing a defined concentration of competitive antagonist with or without acetylcholine. An equilibrium (ϩ/ϩ) protocol was performed by exposing the patch to acetylcholine plus antagonist for 0.25 s, with a 5-s interval of antagonist alone. After switching back to antagonist-free solutions, the control protocol was repeated. 26 Results were accepted if the current amplitudes during the second control were 80% or more of those in the first; usually, the ratio was 95% or more. A recovery (ϩ/Ϫ) protocol was used to determine the time needed for currents to recover after removal of antagonist. This protocol was performed with the same perfusion system by equilibrating the patch with antagonist alone for 5 s and exposing the patch to acetylcholine alone for 0.60 s as described previously. 27 Currents flowing during exposure of the patch to acetylcholine were measured with a patch clamp amplifier (EPC-9; HEKA Elektronik, Lambrecht, Germany), sampled at 100 s per point and stored on a computer. Data analysis was performed off-line as described previously. 26, 27 Experiments were performed at room temperature (20°-23°C) and at a patch potential of Ϫ50 mV unless otherwise indicated.
The ratio of the peak inward current after the rapid onset phase in the presence of antagonist (I ant , ϩ/ϩ protocol) to that in the average of the two control currents, I 0 , was calculated. This provided the fraction of receptors that were inhibited by an antagonist in the absence of acetylcholine. Concentration-response curves were generated from data obtained from experiments performed with six or seven different antagonist concentrations, each used on three to six different patches. Means and SDs are shown in the figures. Individual data points were fitted to the Hill equation:
where [ant] is antagonist concentration, IC 50 is the concentration producing 50% inhibition, and n H is the Hill coefficient. For ␦D180K receptors, control currents were usually less than 20 pA in absolute value. In these experiments, a single concentration point (at twice wildtype IC 50 ) was determined. The rate of recovery from antagonist inhibition (ϩ/Ϫ protocol) was determined from 7-19 measurements of the recovery time constant for 3-5 different patches. The average and SD of the reciprocal of the (concentration-independent) time constant were calculated. This rate was interpreted to be the antagonist dissociation rate, ᐉ Ϫ . 27 The association rate, ᐉ ϩ , was calculated from ᐉ ϩ ϭ ᐉ Ϫ /IC 50 .
Statistical Analysis
IC 50 values for mutant versus wild-type receptors were compared using an F test for nonlinear regression (Prism 4; GraphPad Software, Inc., San Diego, CA). Dissociation and association rates for mutant versus wild-type receptors were compared using a Student t test. P values less than 0.01 were considered significant because five mutants were compared with wild type for each drug. With the ␦D180K mutation, current levels were compared with wild type using an unpaired t test; P values less than 0.05 were considered significant.
Results

Equilibrium Inhibition
Examples of currents in wild-type and ␣Y198F nAChRs in the absence and presence of the five competitive antagonists are shown in figures 2A-E. Rapid perfusion of 300 M acetylcholine elicited macroscopic currents that reached a peak within 0.3 ms and decayed due to desensitization with a time constant of 30 -100 ms. 22 The antagonist concentrations illustrated here were chosen to produce approximately 50% inhibition of the instantaneous inward current in wild-type receptors (left panel). In the presence of 25 nM (ϩ)-tubocurarine ( fig fig. 2E ), the current reached a plateau or exhibited a secondary increase before desensitizing. This is characteristic of competitive antagonists that dissociate from the receptor on a time scale similar to or faster than desensitization. 27 For these currents, the degree of inhibition was calculated from the peak inward current reached within 1 ms of agonist application. The center panel of figure 2 shows currents from receptors containing the ␣Y198F mutation. The antagonist concentrations in this panel are the same as those shown for wild-type receptors in the left panel. The antagonist-dependent effects of ␣Y198F are readily apparent. The mutation caused an increase in the potency of (ϩ)-tubocurarine ( fig. 2A ), a decrease in the potency of pancuronium and vecuronium (figs. 2C and D), and small changes in the potency of metocurine and cisatracurium (figs. 2B and E). The graphs in the right panel of figure 2 show how the concentration-response curves were differentially affected by the ␣Y198F mutation. Table 1 lists the results of fitting the concentration-response curves to the Hill equation for all combinations of antagonist and receptor. The Hill coefficients ranged from 0.8 to 1.3 with the average value being 1.01 Ϯ 0.12.
Although each antagonist has two binding sites on the receptor, functional assays, such as current inhibition, are not very sensitive to the presence of a second, low-affinity site, and the Hill coefficients are expected to be close to 1. 27 The antagonist-receptor combinations producing relatively high Hill coefficients, e.g., cisatracurium-wild type, may have a low-affinity site that is only approximately 10-fold less potent than the highaffinity site.
The effects of mutations on the IC 50 of the competitive antagonists are illustrated in figure 3 , where ratio of the mutant IC 50 to the wild-type IC 50 is plotted for each antagonist. The antagonist dependence of the ratio is clear, not only for the ␣Y198F mutation (shown in fig.  2 ), but also for the D59 and D173 mutations. Therefore, mutations at D59 produced a 13-to 16-fold increase in the IC 50 of metocurine, a 4-to 5-fold increase for cisatracurium, a 2-to 3-fold increase for (ϩ)-tubocurarine, a 1.4-fold increase for vecuronium (only D59A shows a significant change), and no significant change for pancuronium. The sensitivity of antagonists to mutations at D173 showed a distinct pattern from the other mutations.
Role of the ␦ Subunit
It was previously found that the ␣interface represents the high-affinity binding site for (ϩ)-tubocurarine and metocurine. There are few known determinants of antagonist binding on the ␦ subunit. Experiments with ␣ 2 ␤␦ 2 receptors expressed in oocytes showed that mutations at ␦D180 decrease the affinity of (ϩ)-tubocurarine with ␦D180K showing a 16-fold decrease 28 (these receptors have two "low-affinity" sites; the binding constant derived from the inhibition of bungarotoxin binding changed from 337 nM to 5,533 nM due to the mutation). We found that transfection of BOSC-23 cells with ␣ 2 ␤␦ 2 D180K did not result in currents in outside-out patches. Low but finite expression was obtained when ␦D180K was expressed with wild-type ␣, ␤, and . Figure 4 compares the effect of this mutation for inhibition by competitive antagonists when each drug was applied at twice the wild-type IC 50 (which produces a relative current of 0.33 in wild-type receptors). As expected, the mutation did not affect inhibition by (ϩ)-tubocurarine or metocurine because binding to the ␣interface dominates. However, 30 nM pancuronium, 40 nM vecuronium, and 110 nM cisatracurium decreased currents in the mutant ␦D180K receptors less (0.62, 0.73, and 0.59, respectively) than they did in wild-type receptors. This corresponds to a 3-to 5-fold decrease in affinity.
We also measured inhibition with (wild-type) ␣ 2 ␤␦ 2 receptors that are expressed when the cDNA for the subunit is omitted. If the high-affinity site of an antago-
Fig. 2. Examples of current inhibition data for wild-type (WT) and ␣Y198F mutant nicotinic acetylcholine receptor for the five competitive antagonists used in this study: (؉)-tubocurarine (A), metocurine (B), pancuronium (C), vecuronium (D), and cisatracurium (E). Traces in the left panel show inhibition of wild-type receptors for a concentration close to the IC 50 value. Traces in the center panel show inhibition of ␣Y198F mutant receptors for the same concentration of competitive antagonist. Graphs in the right panel show the concentration-response curve for the corresponding competitive antagonist.
nist were the ␣-␦ interface, that antagonist would produce more inhibition than for wild-type receptors. Conversely, if the high-affinity site of an antagonist were the ␣interface, that antagonist would produce less inhibition than for wild-type receptors. The results ( fig. 4) show that pancuronium, vecuronium, and cisatracurium all caused a greater inhibition of ␣ 2 ␤␦ 2 receptors compared with ␣ 2 ␤␦ receptors. Although (ϩ)-tubocurarine and metocurine produced less inhibition of ␣ 2 ␤␦ 2 receptors compared with ␣ 2 ␤␦ receptors, the effect was not as large as would be predicted from their high selectivity for the ␣interface.
Kinetics of Inhibition
The recovery (ϩ/Ϫ) protocol was used to determine the dissociation rate of the antagonist from the receptor. Two examples with vecuronium are shown in figure 5 . The concentration of antagonist used was 3 to 5 times the IC 50 value for that receptor. The control currents are shown in light gray, and the (ϩ/Ϫ) currents are shown in dark gray. If desensitization were not present, the time course of the (ϩ/Ϫ) current would reflect the time it takes for vecuronium to dissociate from the receptor (the rapid perfusion system removes vecuronium from the aqueous phase within 0.5 ms). The rate of desensi- Table 1 * P Ͻ 0.01 compared with wild type. † P Ͻ 0.001 compared with wild type. ‡ P Ͻ 0.0001 compared with wild type.
. Inhibition and Kinetic Parameters Determined for Each Receptor-Antagonist Combination Used in This Study
Fig. 3. The ratio of IC 50 values for mutant receptors compared with wild type (wt).
Note the logarithmic scale for the ordinate axis. Log ratios less than 0 indicate that the antagonist has a decreased IC 50 (increased potency) for the mutant versus wild type; log ratios greater than 0 indicate that the antagonist has an increased IC 50 (decreased affinity) for the mutant versus wild type. Statistical comparison of mutant IC 50 value compared with wild type. • P < 0.01, •• P < 0.001, ••• P < 0.0001 versus wild type using F test.
tization in the control current was used to calculate the fraction of channels that are either open or desensitized in the (ϩ/Ϫ) current. The results of this numerical correction procedure are shown as black traces in figure 5 .
In both cases, the corrected current had a steady state value that was within 10% of the peak current in the control. The corrected current reached the steady state 3.3 times faster with 280 nM vecuronium on ␣Y198F receptors compared with 100 nM vecuronium on wildtype receptors. For each antagonist-receptor combination, the time constant for recovery was independent of antagonist concentration (not shown).
The results of these experiments are tabulated in table 1 as the dissociation rate constant. The association rate constant was calculated from the dissociation rate and the measured IC 50 value. The measured dissociation rates extended over a 260-fold range from 1.4 to 370/s. The association rates were less variable; they extended over a 12-fold range from 0.7 to 8.3 ϫ 10 8 /M/s. Figure 6 shows that mutations affected the dissociation and association rates in different ways. For example, mutations at D173 increased the IC 50 (decreased the potency) of (ϩ)-tubocurarine by increasing the dissociation rate. In contrast, mutations at D59 increased the IC 50 of (ϩ)tubocurarine primarily by decreasing the association rate. The 2-fold increase in the IC 50 of pancuronium by ␣Y198F was the result of a 4.4-fold increase in dissociation combined with a 2.2-fold increase in association. With cisatracurium, nearly all of the mutations affected both the association and dissociation rates. Interestingly, the ␣Y198F mutation caused a large decrease in both association and dissociation, such that there was only a small change in the IC 50 of cisatracurium.
Discussion
These results extend our knowledge of where competitive antagonists bind on the nAChR in several ways. First, we examined a range of antagonists with different structures. Second, we used a functional assay to insure that binding is concomitant with current inhibition. Third, we considered mutations in both the ␣and ␣-␦ interfaces. Finally, we examined not only equilibrium inhibition but also the kinetics of inhibition.
We characterized the inhibition produced by competitive antagonists (table 1). Our results for the IC 50 of antagonists to wild-type adult mouse nAChR are in good agreement with published values. Fletcher and Steinbach 12 studied channels in a stably transfected fibroblast cell line. Electrophysiologic measurements resulted in IC 50 values of 11, 54, 129, and 139 nM for pancuronium, Fig. 4 . Inhibition of wild-type, ␦D180K mutant, and ␣ 2 ␤␦ 2 receptors by competitive antagonists. The antagonist concentrations are twice the wild-type IC 50 values. The ␦D180K mutation does not change the amount of inhibition by (؉)-tubocurarine or metocurine but decreases inhibition by pancuronium, vecuronium, and cisatracurium. This suggests that the ␣-␦ interface plays a role in the binding of pancuronium, vecuronium, and cisatracurium. Similarly, the results with ␣ 2 ␤␦ 2 receptors indicate that the ␣-␦ interface is more important than the ␣interface in determining the affinity of wild-type receptors for pancuronium, vecuronium, and cisatracurium. The results with (؉)-tubocurarine and metocurine are in qualitative but not quantitative agreement with their high affinity for the ␣interface. ** P < 0.001 versus wild type using t test. * P < 0.05 versus wild type using t test. (ϩ)-tubocurarine, metocurine, and atracurium, respectively (they did not study cisatracurium). Measurements on transfected frog oocytes by Paul et al. 29 produced IC 50 values of 5.5, 9.9, and 43.4 nM for pancuronium, vecuronium, and (ϩ)-tubocurarine, respectively. It should be noted that both of these groups studied receptors in the whole cell activated with nonsaturating concentrations of acetylcholine (0.4 M 12 or 10 M 29 ) using relatively slow perfusion systems. The inherent assumption with this approach is that if the antagonists dissociate from the receptor, rebinding by the antagonist is more probable than binding by agonist (and subsequent activation of the channel). In our system, rapid (Ͻ 1 ms) application of a saturating concentration of acetylcholine (300 M) allows measurement of the uninhibited current (and, from this, determination of the degree of inhibition) before the antagonists begin to dissociate. Actual measurement of dissociation rates (Յ 400/s; table 1) validates our approach.
The results of the mutation studies (table 1 and figs. 3 and 4) show that antagonists are affected differentially by mutations. The ␣Y198F mutation in embryonic mouse nAChR was shown to have a greater effect on inhibition by (ϩ)-tubocurarine than by pancuronium. 18 Differences between (ϩ)-tubocurarine and metocurine binding to AChBP 30 and human nAChR 15 were identified by Sine's group. They found that although these two antagonists differ by only three methyl groups ( fig. 1) , they are differentially sensitive to mutations. Our results on mouse nAChR are similar. (ϩ)-Tubocurarine is affected by mutations at ␣Y198, but metocurine is not. Mutations at D59 affect metocurine more than (ϩ)tubocurarine, and the opposite is true for D173. In docking simulations, Sine's group made the surprising finding that these two antagonists assume docking orientations that are rotated by 180°(AChBP 30 ) or 60°( human nAChR 15 ). Our results with pancuronium and vecuronium underscore the sensitive interactions between ligand and receptor. Although both antagonists are affected by the ␣Y198F mutation, mutations in the subunit have small but significant effects on vecuronium and no effect on pancuronium. Inhibition by both of these antagonists is affected by the ␦ subunit mutation, whereas inhibition by (ϩ)-tubocurarine or metocurine is not. Cisatracurium, which is a benzylisoquinolinium compound like (ϩ)-tubocurarine and metocurine, is affected by mutations on the ␣ and subunits similarly to metocurine. However, unlike metocurine, cisatracurium is sensitive to the ␦ subunit mutation and has distinct kinetic responses to mutations.
Binding constants for some antagonists have been obtained through measurements of the reduction of iodinated bungarotoxin binding. These experiments can reveal the affinity of both binding sites for the antagonists, but do not always make an association between the binding constant and a particular site. Although the slope of the electrophysiologically determined concentration-response curve is not a very sensitive way to characterize the lower-affinity site, the relatively high Hill slope for cisatracurium on wild-type receptors (table  1) can be explained if there are two binding sites with affinities of 62 Ϯ 4 and 480 Ϯ 180 nM, respectively. 27 Table 2 summarizes what is known about the selectivity of adult mouse nAChR for competitive antagonists.
We must be cautious about making inferences about selectivity solely from mutation experiments because the lack of effect of a mutation could mean that the mutated residue is either not involved or only weakly involved in binding. Conversely, the presence of an effect by a mutation could mean that the mutated residue is involved in binding or that the mutation caused an allosteric change to affect the affinity of the antagonist. Our mutagenesis results are consistent with previous results showing that the ␣interface as the high-affinity site for metocurine and (ϩ)-tubocurarine. For pancuronium, vecuronium, and cisatracurium, our finding that receptors with a mutation in the ␦ subunit are inhibited more than wild-type receptors suggests that that the ␣-␦ interface is the higheraffinity site. The small and absent effects of subunit mutations on vecuronium and pancuronium respectively also support this idea. Experiments in which the subunit is replaced with a second copy of the ␦ subunit ( fig. 4) were consistent with the idea that pancuronium, vecuronium, and cisatracurium now had two high-affinity binding sites. We could not obtain precise estimates of the interface selectivity of pancuronium or vecuronium. Because cisatracurium is potently affected by mutations in the subunit, this antagonist is not as selective (3-to 8-fold).
Although these ␣ 2 ␤␦ 2 receptors were not inhibited as strongly as wild-type receptors by (ϩ)-tubocurarine and metocurine, this effect was not in quantitative agreement with the results of toxin binding experiments that show high selectivity of these antagonists for the ␣interface. We do not have a simple explanation for this finding. We note, however, that ␣ 2 ␤␦ 2 receptors may perturb the structure of the receptor significantly more than a single site mutation.
Our conclusion differs from the results of a recent study of adult mouse nAChR exposed to pairs of competitive antagonists. 17 The results of that study suggested that (ϩ)-tubocurarine and pancuronium compete for the same binding site. However, those experiments were performed under conditions of relatively low receptor occupancy where synergistic effects are expected to be small. We are currently performing experiments under conditions of high receptor occupancy to clarify this issue.
Our kinetic measurements provide additional information about the binding of competitive antagonists to the nAChR. The ␣Y198F mutation caused a relatively small, 20% decrease in the IC 50 of cisatracurium. However, this was the result of large changes in the kinetics of inhibition: a 3.6-fold decrease in the dissociation rate and a 2.8-fold decrease in the association rate. An equilibrium assay alone might have led to the conclusion that this amino acid plays a minor role in the interaction of cisatracurium with the receptor. One possible interpretation is that cisatracurium encounters ␣Y198 on its journey into and out of its binding site but does not bind too closely to this residue. A similar effect was seen with the effect of this mutation on the kinetics of acetylcholine binding; both the association and dissociation rates decreased by a factor of 2, such that the overall affinity was unchanged. 31 Most of the antagonist/mutation combinations we examined, however, suggest that the dissociation rate is the primary determinant of the IC 50 value. There are some notable exceptions, and we are currently conducting experiments with other analogs of (ϩ)-tubocurarine to better understand these observations.
The results of this study show that our concept of ligand binding sites on receptors must be broad. The interaction of competitive antagonists with the nAChR is strong, leading to nM binding affinities. However, even structurally similar competitive antagonists occupy different positions at the interface between receptor subunits, and some of them prefer different interfaces. Moreover, we have observed pharmacologic differences between mouse and human adult AChRs. 32 This has implications for drug design. Although the amino groups are essential for binding to the acetylcholine binding site, addition of methyl groups to a parent compound may do more than to increase hydrophobicity; it may affect the orientation of the ligand within the site. 30 The presence of two dissimilar binding sites means that drug design can follow two independent pathways and that pairs of drugs with opposite site preferences may act synergistically. This understanding was made possible by advances in structural and molecular biology. Increased resolution of the conformations of other receptor proteins will probably reveal similar intricacies in the binding of ligands to those proteins. 
␣-␦
Selectivity is defined as the ratio of the low-affinity binding constant to the high-affinity binding constant. The current study provided the high-affinity interface information for pancuronium and cisatracurium. Superscript numbers refer to references.
